NCT07603102 · RECRUITING

Mindfulness With Dual-Task Training in Post-Stroke Mild Cognitive Impairment

This study tests whether combining mindfulness with dual-task training (doing a thinking task while moving) can improve memory, thinking, and physical performance in people with mild cognitive impairment after a stroke. It is compared with aerobic training and health education. Phase is not applicable, which is common for behavioral studies.

You may qualify if

  • Diagnosis of stroke confirmed by computed tomography (CT) or magnetic resonance imaging (MRI).
  • Time since stroke onset ≥3 months and medically stable.
  • Presence of mild cognitive impairment after stroke, defined by a Montreal - - Montreal Cognitive Assessment (MoCA) score \< 26.
  • Mini-Mental State Examination (MMSE) score ≥ 24.
  • Ability to walk independently with or without an assistive device for at least 10 meters.
  • Stable medication regimen for at least 4 weeks prior to enrollment.
  • Ability to understand study instructions and provide written informed consent.

You're excluded if

  • Severe aphasia, visual impairment, hearing impairment, or communication disorders that interfere with assessment or training participation.
  • Severe depression or other major psychiatric disorders.
  • Other neurological diseases affecting cognition or movement (e.g., Parkinson's disease, multiple sclerosis, traumatic brain injury).
  • Severe musculoskeletal, cardiovascular, or systemic diseases that contraindicate exercise participation.
  • Participation in other structured cognitive or rehabilitation intervention programs within the past 3 months.
  • Unstable medical condition or recurrent stroke during the study period.
  • Inability to safely complete the training protocol as determined by the study investigators.

The sponsor's own eligibility wording, lightly reformatted. The study team makes the final eligibility decision — worth discussing with your doctor.

Eligibility criteria as of 2026-05-22

View full record on ClinicalTrials.gov

All APOE4 clinical trials